More vaccines on horizon, says Anivax CEO Buttery
John Buttery was named CEO of Anivax, which is commercializing its patented technology developed to reduce the incidence of campylobacteriosis, a common bacterial foodborne illness in humans.
Anivax’s initial vaccine for poultry was developed through collaborative research at the University of Arizona, Arizona State University and Washington University, supported by the U.S. Department of Agriculture, National Institutes of Health, international research collaborations and institutional support.
“I look forward to developing world-class vaccines in Tucson,” Buttery said in a news release.
Buttery is an executive in residence at the UA’s Tech Launch Arizona. He earned his B.S. in finance and MBA from the UA.
